

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 of 15(d) of the
Securities Exchange Act of 1934

March 22, 2010

Date of Report (date of earliest event reported)

CYTODYN INC.

Exact name of Registrant as Specified in its Charter

Colorado

000-49908

75-3056237

State or Other Jurisdiction
of Incorporation

Commission File
Number

IRS Employer Identification
Number

1511 Third Street, Santa Fe, New Mexico 87505

Address of Principal Executive Offices, Including Zip Code

(505) 988-5520

Registrant's Telephone Number, Including Area Code

Not applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

The Company issued a press release on March 22, 2010 (attached hereto as
Exhibit 99) regarding accelerating the collection of two data points in the
clinical trial being conducted by Massachusetts General Hospital.

The Company has agreed to provide an additional \$204,000 to Massachusetts
General Hospital in connection with the current clinical trial of Cytolin(R),
the Company's novel immune therapy for treating HIV/AIDS. This will enable the
Principal Investigator to hire two additional personnel in order to ensure that

two key data points from the study will be available by December 31, 2010. For details about the clinical trial visit <http://clinicaltrials.gov> and enter Cytolin as a search term.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

- (a) Financial Statements of Businesses Acquired.

Not Applicable.

- (b) Pro Forma Financial Information

Not Applicable.

- (c) Shell Company Transactions

Not Applicable.

- (d) Exhibits

Exhibit 99 Press Release regarding the Company to Increase Study Budget to Accelerate Clinical Trial dated March 22, 2010

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTODYN INC.

Date: March 22, 2010

/s/ Allen D. Allen

Allen D. Allen
President

Exhibit 99.1

SANTA FE, N.M.--(BUSINESS WIRE)--CytoDyn, Inc. (Pink Sheets:CYDY - News) has agreed to provide an additional \$204,000 for the current clinical trial of Cytolin(R), the Company's novel immune therapy for treating HIV/AIDS. This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010. For details about the clinical trial visit <http://clinicaltrials.gov>. and enter Cytolin as a search term.